Variant · Other
FGFR2 Alteration
CI-VAR-00000187Explore in graph →CIViC 4795
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38354330
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| FGFR1 Alteration OR FGFR2 Alteration | Sunitinib | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11883In this phase II clinical trial, 40 patients with breast cancer harboring either FGFR1 or FGFR2 alterations (amplifications or mutations) were recruited. Of the 40 patients, 30 had FGFR1 alterations (… (full text at CIViC) PMID 38354330 · Calfa et al., 2024 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.